By co-expressing CXCR5 and CCR6, we engineered HER2-CAR T cells with enhanced homing capacity, specifically addressing the unmet therapeutic need in this refractory NSCLC subgroup. This evidence concerns the gene CCR6 and non-small cell lung carcinoma.